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Jlips & Coils
Treating Brain Aneurysms

he fall/winter 2003-2004 issue of Focal Spot provided a glimpse
of the construction—an additional underground vault as well as
b.

control, computer, equipment, and instrument rooms—underway at

the Scott Avenue Imaging Center in preparation for the delivery of a new magnetic resonance scanner. The massive, ultra-high field (11.75-tesla) scanner
was recently installed, as shown here, and will aid research in the Biomedical
Magnetic Resonance Laboratory.

FOCAL SPOT
SPRING 2004
VOLUME 35, NUMBER 1

OPTICAL IMAGING: SHEDDING LIGHT ON HIDDEN TUMORS

Researchers in the Optical Radiology Laboratory work with
high-resolution optical imaging systems interfaced with positron
emission tomography, computed tomography, and magnetic
resonance to develop better modalities for diagnosing and
treating diseases.

IMPROVING THE ODDS FOR SURVIVING LUNGCANCER

A National Cancer Institute-funded multicenter
study comparing the effectiveness of spiral
computed tomography and chest X-ray screening
combined with the investigation of advanced
treatment modalities are part of a joint offensive
to reduce lung cancer deaths.

CLIPS AND COILS

SPOT NEWS

A large-scale study shows that patients with
subarachnoid hemorrhage who live in the St. Louis
area have a better survival rate because of the
number of cases treated at Washington University
Medical Center and the expertise of the Medical
Center's neuroradiologists and neurosurgeons.

TRACKING ELUSIVE PROSTATE CANCER

24

FYI

Two important nuclear medicine studies are
using positron emission tomography and the
radiopharmaceutical HC-acetate to diagnose
recurrent prostate cancer and to determine
metastases in newly diagnosed, high-risk patients.

ON THE COVER Neurosurgeon Ralph Dacey and Intervention^ Neuroradiologist DeWitte

Visit the MIR web site at
www.mir.wustl.edu

Cross offer a joint approach to treating subarachnoid hemorrhage by using surgical and
endovascular techniques. Photography by Tim Parker.

►TNEWS
36th Wilson
Award
presented
Kelsey Moran, a fourthyear Washington University in
St. Louis medical student,
received the 2003-2004 Hugh
M. Wilson Award for Meritorious Work in Radiology. The
award has been presented for
36 years in honor of Doctor
Wilson, Mallinckrodt Institute's second director and an
advocate of the advancement
of education.
During his radiology rotation, Moran worked with Sanjeev Bhalla, MD, assistant
professor of radiology and
codirector of body computed
tomography, on a compilation
of "CT findings in unilateral
Glenn/Fontan mimicking pulmonary embolisms." The
manuscript detailed the difficulties encountered in using
computed tomography (CT)
to detect emboli in the pulmonary arteries— because of
the location in the small or
medium pulmonary arteries—
of patients who have had a
Glenn shunt inserted or have
undergone the Fontan procedure to treat tricuspid atresia,
a congenital heart disease.
According to Fernando
Gutierrez, MD, professor of
radiology, Moran demonstrated "his ability to work
with other departments and
come up with joint research.
He worked with Doctor Ludbrook [Philip Ludbmok, professor of medicine and of
radiology, and director of the
Centerfor Adults with Congenital Heart Disease],
putting together the necessary
clinical data for the manuscript, and required very little
supervision in getting the task
done."

New MRI textbook available
Practical Guide to
Abdominal & Pelvic MRI, a
new textbook published by
Iippincott Williams &
Wilkins, is a handy reference
for practicing radiologists, for
residents preparing for board
examinations, and for MRI
technologists. According to
coauthors Jeffrey Brown, MD,
associate professor of radiology and codirector of magnetic resonance imaging
(MRI), and former Mallinckrodt Institute Alumnus John
Leyendecker, MD, assistant
professor of radiology, Wake
Forest University Baptist
Medical Center, WinstonSalem, North Carolina, the
book is a "see what you can
do" rather than a "see what
we can do" reference.

The 268-page book contains concise descriptions,
high-quality illustrations, and
the most common clinical
cases encountered in daily
practice. Its four sections
cover essential physical principles, reviews of specific
abdominal and pelvic MRI
examinations, common differential diagnoses and aids for
interpreting preoperative
imaging studies, and abdominal and pelvic MRI anatomy
reviews. Also included are
sections covering MRI
anatomy, terminology, and
frequently asked questions.

WUSM retains
national
ranking
According to a U.S. News
& World Report survey
released April 2, 2004, Washington University in St. Louis
School of Medicine (WUSM)
ranked second in the nation—
for the second consecutive
year. Harvard University took
first-place honors; following
WUSM were Johns Hopkins
University, Duke University
and the University of Pennsylvania (tie), the University of
California-San Francisco, and
the University of Michigan.

U.S. News & World
Report initiated the professional and graduate school
rankings in 1987. WUSM annually has placed in the top 10
schools and, since 1998, has
ranked first in student selectivity. WUSM departments
and programs also earned
high marks: physical therapy
program ranked second; occupational therapy, third; pediatrics and medicine, seventh.
A complete listing is online at
news-info.wusti.edu/rankings.

Journal honors
MIR reviewers
Since 1985, the Editorial
Board of Radiology, a leading
scientific journal, annually has
honored the most prolific
manuscript reviewers. The
recipients of the 2003 Editor's
Recognition Awards were
announced in the journal's
April 2004 issue. Among the
recipients were the following
MR faculty:
With Special Distinction
• Louis Gilula, MD, professor
of radiology, of orthopaedic
surgery, and of plastic and
reconstructive surgery
With Distinction
• Kyongtae Bae, MD, PhD,
assistant professor of
radiology and of biomedicil
engineering
• David Rubin, MD, associate
professor of radiology.
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Carlos Perez, MD

Perez named
Radiation
Oncology
Teacher of
the Year
The radiation oncology
residents annually select the
Teacher of the Year recipient
by nominating and voting for
the faculty member who
makes a significant contribution to radiation oncology resident education during the
academic year. The award
traditionally is presented each
year in December.
Carlos Perez, MD, professor of radiation oncology and
chairman of the Department
of Radiation Oncology, was
selected as the 2003 Teacher
of the Year. This is a special
honor for Perez, as he also
received the award in 1990.
He joined the MIR faculty in 1964 and was named
director of the Radiation
Oncology Center in 1976. In
June 2001, he was named
chairman of Washington
University's newly formed
Department of Radiation
Oncology.
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Perez is one of the
world's most highly regarded
radiation oncologists and has
received many honors in
recognition of his scientific
contributions, including
Gold Medal awards from the
American College of Radiology, the American Society for
Therapeutic Radiology and
Oncology, and CRILA/Circulo
do Radioterapeutas IberoLatinoamericanos, as well as
the American Radium Society's Janeway Medal. He is
coeditor of the textbook
Principles and Practice of
Radiation Oncology, now in
its fourth edition and hailed as
"the most comprehensive
textbook of radiation oncology available."

Perlmutter
receives honors
Joel Perlmutter, MD, professor of neurology, of neurological surgery, and of
radiology, was named to the
2004-2005 Marquis8 Who's
Who in Medicine and Healthcare. The Marquis Who's Who
biographical series has been
published since 1989, and the
medicine and healthcare vol-

ume provides information on
the field's successful educators, researchers, clinicians,
administrators, and industry
leaders. Perlmutter, who heads
the Department of Neurology's
Movement Disorder section, is
a nationally recognized expert
in the study of physical and
chemical factors associated
with Parkinson disease and
dystonia.
In April 2004, Perlmutter
received the Mentor Award,
presented by the Washington
University in St. Louis School
of Medicine's Academic
Women's Network. The award
has been presented annually
since 1994 to faculty members
who have served as outstanding mentors to the University's
female faculty members or
trainees.

Society's
Annual
Meeting to
be in St. Louis
The Society for Molecular
Imaging (SMI), an international
scientific education organization, will holds its third annual
meeting September 9-12, 2004,
at the Adam's Mark Hotel in
St. Louis. The key focus of the
meeting is new insights into
mammalian biology acquired
through imaging. Other topics
include advanced molecular
imaging approaches in biology
and medicine, advances in
positron emission tomography
and single photon emission
computed tomography, optical
tomography and low-light
imaging, and research and
industrial collaborations. Early
discounted registration rates
are available on or before July
9, 2004. Register online (with
credit card) at www.molecularimaging.org, or call (650)
216-6621 for more information.

David Piwnica-Worms,
MD, PhD, professor of radiology and of molecular biology
and pharmacology, is SMI
president and chairman of the
meeting. Joseph Ackerman,
PhD, professor of chemistry,
of medicine, and of radiology,
and chief of the biomedical
magnetic resonance imaging
laboratory, and Michael Welch,
PhD, professor of radiology,
of chemistry, and of molecular
biology and pharmacology,
and cochief of the Division of
Radiological Sciences, are
meeting cochairmen.

Matching Program results
announced
In June, 19 physicians
will begin their first year of
training in diagnostic radiology. These promising trainees
come to MIR from excellent
medical schools: Emory University (2); Harvard University
(2); New York University (1);
University of California, San
Francisco (1); University of
Iowa (1); University of
Louisville (1); University of
Pennsylvania (2); University
of Washington (1); University
of Wisconsin (1); Washington
University in St. Louis (6);
Yale University (1).
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on Hidden Tumors

THE LIGHT WE DON'T SEE CAN SAVE OUR LIVES.

B

t's absolutely amazing what we can do with light. In the visible light range, 400 to 750 nanometers

- (1 billionth of a meter), humans have body tissues that attract and absorb light: melanin, proteins, am
oxyhemoglobin. This propensity for selective tissue absorption has led to the development of lasers for hai
removal, spider vein dissolution, treatments for the rosacea "blush" of adult acne, and even removal of ad
spots—all very popular procedures with people needing these services. While these breakthroughs are valuabll
in themselves, light and optical imaging have now moved into important diagnostic and therapeutic realms.
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Near-Infrared Imaging
To look deeper into our bodies
for the secrets of diagnostic and
healing applications, we have to
move away from the visible light
range, away from the surface
attractants. Samuel Achilefu, PhD,
is interim chief of the Optical
Radiology Laboratory at Mallinckrodt Institute of Radiology (MIR).
His work revolves around the
diagnostic applications of the
near-infrared spectrum of light in
the 750 to 900 nanometer range.
Researchers in the Optical
Radiology Laboratory (ORL),
established in 1999, work with
high-resolution optical imaging
systems. "We are gradually assembling the personnel and equipment
we need. It takes a combination of
several different technologies,"
says Achilefu, an associate professor of radiology. "Using optical
spectroscopy in the visible wavelengths, we can penetrate only a
few millimeters into tissues.
However, when we perform
optical imaging through diffused
optical tomography, we can delve
several centimeters into tissue,
depending on the instrument and
methodology."
In biological systems,
researchers have found that light
absorption and scattering are
in the right interpretive
modes, indicative of physiologic states. Research on the
brain with optical imaging
has shown that hemoglobin spectroscopy of the
different brain regions
can reveal internal bleeding caused by head
injury. In the breast,
increased blood volume
or vascularity can pinpoint tumors.
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TO

look deeper into our bodies...

we have to move away from the visible light range, away
from the surface attractants.

How Optical
Imaging Works
As Achilefu explains, light scatters when it hits tissue. Computer
algorithms can correct for the scattering. An algorithm is a formula or
set of rules for solving a particular
problem—in this case, where the
light would have gone had it not
scattered. Using these algorithms
to reconstruct the path of light
after scattering can create slices of
tissue as would a computed tomography (CT) scan or a magnetic
resonance imaging (MRI) scan.
"The optical methods
are highly sensitive
and can
detect minute

amounts of light-sensitive materials. In this lab, we are developing a
state-of-the-art diffuse optical
tomography, or DOT, system and
molecular beacons to use as a contrast agent for optical imaging. We
now have the ability to study brain
function, angiogenesis, and protein
expression in tumors as well as
metastases," says Achilefu.
As principal investigator,
Achilefu received a National Institutes of Health-funded project to
interface optical imaging and
positron emission tomography

■ ■ ■ ■ ■
(Left to right) Researchers Sachin Patwardhan,
Sharon Bioch, and Joseph Culver are shown with a
diffused optical tomography (DOT) system developed and built in the Institute's Optical Radiology
Laboratory.

Opt

Imaging

(PET) imaging into a hybrid technology. Barry Siegel, MD, chief of
the Division of the Division of
Nuclear Medicine, and Michael
Welch, PhD, cochief of the Division
of Radiological Sciences, are active
collaborators on the research. "We
still have the problem of localization in deep tissue by optical methods. That's where PET comes in,"
says Achilefu. "We use PET to
map the area to get a baseline.
Then we can monitor the
status of the disease
by optical methods, picking
up fluorescent traces

in the near-infrared region after the
PET radioisotope decay. An advantage of optical imaging is that it is
nonionizing, or nonradioactive."
Another promising interface is
between CT or MFJ scanning and
optical imaging. CT has a high
structural resolution; optical imaging delivers high functional information. According to Achilefu, CT
will be performed in conjunction
with optical imaging soon in
humans. The imaging techniques
scan the same tissue but are asking
different questions. "CT asks
where the margins of the
tumor are. Optical interrogates the functional status of the cells at the
margins. When patients
with cancer are treated,
we sometimes have to
wait for months to observe
the effectiveness of the
treatment regimen, which
can be manifested by
reduction in tumor
size, as evidenced
by MFJ or CT
scans," says
Achilefu. "Within
days, optical
imaging can
detect the
response of
tumors to treatment. We can
see—or not
see—changes
within weeks
instead of
months, which
speeds up the
process of finding effective
interventions."

The Future of
Optical Imaging
On a list of potential applications
for optical imaging are brain function
and cervical, colon, gastrointestinal
(GI), prostate, and breast cancer,
which present viable targets by noninvasive DOT or endoscopy. "Noninvasive breast imaging or
spectroscopy in the MR [nearinfrared] wavelengths is particularly
attractive; because of the breast's
anatomy, a probe can be placed
around it and iUumination can be
obtained from multiple directions:
up, down, side-to-side, frontally. We
can triangulate images and get much
better three-dimensional identification," explains Achilefu. "In contrast,
imaging deep organs noninvasively,
such as the liver, is a challenge
because of the attendant poor image
resolution that results from multiple
light scattering in deep tissues. We
currently cannot scan different
views of such organs by optical
methods. Researchers in the ORL
are working now on validation studies using small animals. In two years,
we hope to be doing clinical testing
with patients."
According to Achilefu, unlike
MRI or PET, which use radioactive
tracers, optical equipment does not.
"Optical imaging can be performed
safely in a physician's office and
organ function can be monitored in
real time. It is an exciting area"
He is especially interested in
combining the diagnostic and therapeutic potential of optical methods.
"Optical methods give us the opportunity to 'see and treat' diseases. The
treatment arises from substances
that are triggered by light to destroy
only the diseased cells where it is

Samuel Achilefu is shown in the Optical Radiology Laboratory, in an area
where researchers work on systems to combine magnetic resonance and
optical imaging.

MALLINCKRODT INSTITUTE OF RADIOLOGY

localized," says Achilefu. "This
approach is called photodynamic
therapy. In the ORL, we are developing these dual-role materials, which
can be used to perform both imaging
and treatment. I call these drugs
'diapeutics,' an acronym for combining diagnostic and therapeutic
effects into one drug."
"The longer the wavelength, the
lower the energy," he adds. "Diapeutics have two components that can
absorb two different wavelengths.
Activation of the drug at a longer
wavelength helps the physician discern the exact nature of the problem
without distracting surface absorptions. Then the light of a shorter
wavelength can be used to treat the
diseased tissue, working by photosensitive molecular excitation. Light
of the appropriate wavelength produces free radicals that are toxic to
surrounding cells. At some point, we
will be able to do diagnosis and treatment by optical methods alone."
In the field of biological imaging,
Mallinckrodt Institute's ORL is moving toward complete integration of
multiple modes of imaging. Joseph
Culver, PhD, an expert in DOT,
recently joined the ORL and will play
a vital role in the development of
highly sensitive DOT systems. DEI

Achilefu and his colleagues are closely
watching research at Johns Hopkins
and Clemson universities where light
absorbing and scattering parameters
are being used as a noninvasive
approach to distinguishing between
breast cancers and benign tumors like
fibroadenomas. Watch for more information in upcoming issues of Focal
Spot magazine.
A closer look at the prototype DOT system to
detect brain function and certain types of cancer.
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The ORL will play a major role in Biomed 21, Washington University School
of Medicine's strategic plan for developing a multidisciplinary approach to
basic and clinical research. Named for its potential for advancing research
and clinical practice in the 21s' century, BioMed 21 will include components
such as the Genome Sequencing Center, The Genome Sciences and
Human Genetics Program, the Division of Clinical Sciences, and the Center
for Biological Imaging—where the ORL will shine.

Optical Imaging Laboratory
Samuel Achilefu, PhD, associate professor of radiology
and interim laboratory chief
Mikhail Berezin, PhD, research associate
Sharon Bloch, PhD, research associate
Joseph Culver, PhD, assistant professor of radiology
Kexian Liang, research technician
Nancy North, secretary
Sachin Patwardhan, PhD, research associate
Yunpeng Ye, PhD, research associate
Zongren Zhang, PhD, research associate
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Improving the Odds for

Surviving Lung Cancer
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IMAGING AND COLLABORATION ARE KEY TO IMPROVING SURVIVAL RATES
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THE TECHNOLOGY-FUELED WAR AGAINST LUNG CANCER IS HEATING UR
UNLIKE MANY OTHER CANCERS, ITS DEATH RATES HAVE NOT DECLINED. REDUCING THE TOLL
OF THIS DEVASTATING DISEASE CAN ONLY HAPPEN WITH A JOINT OFFENSIVE IN DIAGNOSIS AND
TREATMENT. MALLINCKRODT INSTITUTE OF RADIOLOGY (MIR) AND THE DEPARTMENT OF
RADIATION ONCOLOGY ARE PARTNERS IN THIS FIGHT, EACH CONTRIBUTING RESEARCH AND
CONSULTATION TO THE OTHER FOR ENHANCED RESULTS.

IMPORTANCE OF
EARLY DETECTION
Experience tells us that the
earlier a catastrophic condition is detected, the more
treatable it is and the better the
outlook for cure. The rub comes in
how we define "early." Concerning
lung nodules, early can have several meanings: still small in size,
confined to one area, or at an
early stage. In 15 percent to 30
percent of the cases, by the time
symptoms have led to detection,
the cancer has already spread
outside the lung.
NATIONAL LUNG
SCREENING TRIAL
The National Lung Screening
Trial (NLST) began in 2002,
with a goal of comparing spiral computed tomography (CT) and
chest X-ray screening for their
effectiveness in reducing deaths
from lung cancer. The NLST
involves 30 sites across the country
and combines data collected from
the Prostate, Lung, Colorectal and
Ovarian (PLCO) trial network that
started 10 years ago and the American College of Radiology Imaging
Network (ACRIN).

David Gierada, MD, an associate professor of radiology with
expertise in chest radiology and CT
imaging, is coprincipal investigator
for the NLST at Washington University in St. Louis. He reports that the
enrollment of 50,000 former or
current smokers nationally was
reached in February 2004—
more than six months ahead of
schedule. The St. Louis site has
3,800 participants enrolled.
Eligible participants are randomly assigned to receive either a
chest X ray or a spiral CT scan.
They receive an initial screening,
with a repeat screening at years
one and two. Then participants
will receive follow-up tracking
through 2009.
"Spiral CT allows identification
of lung nodules at a smaller size
than a chest X ray does, but we
don't know whether these patients
will survive longer. We expect the
smaller tumor to be more treatable," says Gierada. "However, not
all small tumors exhibit the same
behavior. Some small tumors can
spread early. Other tumors have a
very slow growth rate; so even if
they go undetected, they may not
result in the patient's death, analogous to what is often observed with
prostate cancer.

In addition to tumor size, the
study gathers data on nodule
characteristics and the staging of
known cancers, which takes into
account not only tumor size but
lymph node involvement and any
detected distant metastases. The
higher the stage, the worse the
survival outlook. Given all those
tumor variables, and the fact that
only a small percentage of NLST
participants are expected to die
from lung cancer during the course
of the study, the NSLT is looking
for data from the 50,000 participants to determine whether one
type of screening is more effective
than the other at reducing lung
cancer deaths.
In the NLST, if participants
have positive screenings (denned
as a nodule equal to or greater than
4 millimeters) that information is
given to the patients and their
primary physicians with recommendations for follow-up care.
Unanswered questions still exist
because most nodules are not cancerous. All positive test results are
followed up to determine outcome.
One option for patients is to be
seen in the Surveillance of Pulmonary Indeterminate Nodules
(SPIN) clinic. Patients may selfrefer or be referred by their attending physicians. Nearly half of the
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Surviving Lung Cancer

SPIN clinic patients come from the
NLST. Patients are seen by Washington University thoracic surgeons
and advanced nurse practitioners
experienced in dealing with the
issues. "We can do further testing
with a variety of radiological techniques to help distinguish malignant tumor from benign nodule.
If the nodule is cancerous, we
assist in staging and identifying
the appropriate treatment options,"
says Gierada.

Study participants return annually for screening and/or to update
their medical history: What they
did about the test's positive results,
whether follow-up care resulted in
a diagnosis of lung cancer, and ,
what treatment they had. In addition to detecting cancer early, an
important objective of the study is
to minimize the number of procedures done on benign lesions.
There are additional benefits
of the NLST. All the generated data
can be used to determine what
features of the identified nodules
make them more or less likely to
be malignant, such as the behavior
of different sizes and shapes of
nodules in different parts of the
lung. The CT image data will be
available to researchers through a
centralized library, containing all
CT scans performed at PLCO
screening centers, and will be
located and managed in MIR's
Electronic Radiology Laboratory.
COORDINATION OF DIAGNOSIS
AND TREATMENT
For patients who are diagnosed
with lung cancer and will be
treated at the Washington University Medical Center, a multidisciplinary group meets weekly to discuss
possible treatment plans. Thoracic
surgeons, medical oncologists,
pathologists, radiation oncologists,
and diagnostic radiologists all collaborate. When a case is presented,
all group members contribute their
data and discuss appropriate treatment. Diagnostic radiology plays an
important role in helping to stage
a tumor by employing a variety
of techniques and directing treatment options.

chest radiograph (Fig. A) and low dose -.
scan (Fig. B) show lung cancers detected in two
National Lung Screening Trial participants at Washing-

IF THE NODULE IS
CANCEROUS, WE
ASSIST IN STAGING AND
IDENTIFYING THE APPRO
PRIATE TREATMENT OPTIONS.

TREATING LUNG CANCER
The second critical piece in the
war on lung cancer is the advancement of treatment modalities,
particularly in the area of radiation
therapy. According to Jeffrey
Bradley, MD, assistant professor of
radiation oncology, most patients
with lung cancer benefit more from
surgery. If the tumor is not operable, then radiation treatment is
increasingly a good choice.
Approximately three fourths of
patients with lung cancer will need
radiation treatment, with or without surgery. The Department of
Radiation Oncology offers the latest in imaging and treatment for
lung cancer. Three-dimensional
conformal radiation therapy (3DCRT), using a combined positron
emission tomography (PET) and
CT scanner, allows clinicians
simultaneously to localize and target lung cancers more accurately
and to deliver more effective doses
of radiation to the tumor, while
sparing adjacent healthy tissue.

ton University in St. Louis. The right lung lesion i
chest radiograph measures 2 cm in diameter; tu
'on on the CT scan measures 1 cm in di

10

MALLINCKRODT INSTITUTE OF RADIOLOGY

Hi

CAD Differentiates Lung Nodules
"PET/CT is ideal for radiation planning," says Bradley,
who sees patients at Siteman
Cancer Center in the Center for
Advanced Medicine. "Before
three-D-CRT technology, treatment was more for symptom
control than for cure. Parts of
the tumors often received lower
doses of radiation in order to
spare healthy tissue nearby.
We've found that since the
development of three-D
conformal therapy in the 1990s,
delivery of radiation specifically
to the tumor has been improved.
And with small inoperable
tumors, we may be achieving a
higher cure rate, which has led
to more aggressive treatment."
Bradley is basing this information on his retrospective
study of 207 patients treated at
Washington University Medical
Center with 3D-CRT between
1991 and 1998. "For a patient
with lung cancer whose tumor
isn't treated with surgery, the
traditional staging system may
not be the right approach. Based
on our findings, total tumor volume may be more important,"
he says.
Tumor volume refers to the
total size of the tumor and any
affected lymph nodes. When the
study data was analyzed, age,
tumor stage, and any adjunct
chemotherapy were dropped
out of the equation, leaving total
tumor volume. The average survival rate for the 207 cases with

T
At Mallinckrodt Institute of Radiology, computeraided diagnosis (CAD) is being used to aid in the
automated detection and characterization of
lung nodules and focal ground-glass opacities [nonsolid
opacities]. Ty Bae, MD, PhD, associate professor of radiology,
is at the forefront of this research. He sees CAD as an aid to
the skilled radiological practitioner, contributing in four main
areas to lung cancer diagnosis:
> Computer algorithms simulate the human detection process. The algorithm is a set
of rules or steps a programmer designs, a decision tree that allows the program to do the job it is
designed to perform. Says Bae, 'There are certain radiological tasks that computers can do better
than humans, like measuring area and volume, and having an almost unlimited ability to remember numbers and images from a previous study for comparison to the current study. But beyond
that, the experienced radiologist is probably better overall at performing most diagnostic tasks."
> Consistent performance. Even skilled radiologists have a fatigue factor when going
through hundreds of images to detect small modules. "If a radiologist reviews twenty cases in a
day, he or she has to scrutinize a couple thousand images and has to detect and document
nodules and other findings seen in each image. With CAD integration, the computer can help
flag and document nodules for the radiologists, thus improving their diagnostic performance and
work flow. The computer has been over ninety percent successful in identifying very small lesions,
and it has no fatigue factor," says Bae.
The lung is a unique organ because it is full of air, which provides a good contrast to soft tissue.
Within the lung tissue, structures are either vessels or nodules. "With CT scans, we are looking at
very thin cross-sectional slices of the chest cavity. The pulmonary vessels are typically perpendicular
to the image plane. On each image, a nodule is round, and so is a cross section of an artery. We
differentiate the nodule and vessel by visually examining the structural continuity between adjacent
slices. Our CAD system can easily track lung structures and evaluate their three-dimensionality
mathematically, separating the nodules from the vessels over multiple slices," explains Bae.
> Nodule characteristics. Says Bae, "After a nodule is identified, then we must determine the
characteristics that make it more or less likely to be cancerous. For instance, we look at calcification. If the nodule is completely calcified, it is benign. Unfortunately, most nodules are indeterminate without definite morphologic signature, so we repeat the CT scan after some time interval to
follow their growth pattern. Rapid growth usually means cancer. The CAD program measures
the difference in nodule volumes between the initial and follow-up CT scans and may detect early
growth not obvious to the human eye—then the radiologist can act on it more quickly."
> Reporting speed. "After the detection, CAD can facilitate reporting the three-dimensional
location and volume over many slices, time and time again—much more quickly than a human
can," say Bae.
Bae and his research team is currently developing the tools needed for small-scale clinical
studies at Mallinckrodt Institute in 2005 to evaluate the utility of CAD for improving the detection of
lung nodule and focal ground-glass opacities.
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all tumor sizes treated with 3D-CRT
was 59% after one year and 41%
after two years. Patients with
tumor volumes of three cubic centimeters or less had a tumor-specific survival rate of 78% for both
year one and year two, as compared with 51% after year one and
29% after year two for those
patients with the largest tumors.
Bradley's study indicated that
3D-CRT may be a good alternative
for patients whose tumors could be
surgically treated but for whom
surgery itself would be risky. It also
suggested that patients with large
tumors should be treated less
aggressively, using radiation for
symptom control.
Another treatment that shows
great promise, according to
Bradley, is the use of stereotactic
high-dose radiation for patients
who are prescribed a combination
of surgery and radiation. Stereotactic radiation involves a number

MOST PATIENTS WITH LUNG CANCER BENEFIT
MORE FROM SURGERY. IF THE TUMOR IS NOT OPERABLE,
THEN RADIATION TREATMENT IS INCREASINGLY A GOOD CHOICE.

APPROXIMATELY THREE FOURTHS OF PATIENTS WITH LUNG CANCER
WILL NEED RADIATION TREATMENT, WITH OR WITHOUT SURGERY.

of precisely aimed beams of ionizing radiation—each coming from
different directions and meeting at
a specific point—to deliver the
radiation dose. "In order to deliver
a stereotactic dose, lung movement
during breathing must be controlled. The Department of Radiation Oncology has new equipment
that immobilizes the chest and
allows only shallow breathing for a
short period. We plan to start treating patients with this technique
soon, but still utilize the targeted
three-D-CRT approach. It's the

most technologically advanced
form of three-D-CRT," he says.
Physicians in Japan and
Germany have been using the
technique for five years, and the
reports are encouraging. "Physicians at the University of Indiana
and at other medical facilities
have begun treating patients with
this technology. The Radiation
Therapy Oncology Group (RTOG)
is starting a long-term trial involving ten to twenty institutions to
track the procedure's effectiveness," says Bradley, who received
his 3-D training in Germany.
Other areas being explored
are 4D-CT simulations that control lung motion during breathing
and can deliver a burst of radiation during the same position in
the respiratory cycle. Says
Bradley, "Everything we do in
the Department of Radiation
Oncology is based on imaging."
Add the early detection
technology being investigated
at Mallinckrodt Institute of
Radiology to the Department
of Radiation of Oncology's
image-based treatment modalities, and this war on lung cancer
could be won. EM
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> Lung cancer is the leading
cause of cancer death in both
men and women in the United
States.
> Lung cancer is the ITlOSt
preventable type of cancer.
> Smoking cigarettes, cigars, or a
pipe is the number one
Cause of lung cancer; smoking
accounts for 87% of lung cancers.
The longer a person has smoked
and the more cigarettes smoked
per day, the greater the risk of
developing lung cancer.
> The incidence for lung cancer in
African-American males is
approximately 50 percent
higher than in their white counterparts; the death rate is 27
percent higher.
> An estimated 174,000 people
in the United States will be
newly diagnosed with lung
cancer in 2004.
> An estimated 160,000 people
in the United States will die from
lung cancer in 2004—approximately 92,000 males and 68,000
females.
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> There are two major types of lung
cancer: non-Small cell (more
common, usually metastasizes
more slowly) and small cell
(also called oat cell). Small cell
lung cancer accounts for approximately 20 percent of all lung
cancers and is usually caused by
smoking.
> Depending on the type and stage,
lung cancer is usually treated by
surgery, radiation therapy, or
chemotherapy—either alone
or in combination.
> The number of Americans getting

lung cancer is decreasing,
primarily due to the decrease
in adult smoking over the past
30 years.
> Smoking among teenagers and
adolescents has increased in
recent years. The increase
can cause a potential rise in lung
cancer incidence in future years
as this population ages.

> Early-stage lung cancer
usually does not cause
Symptoms. The following
symptoms may occur but may
not indicate lung cancer and
could be signs of a less serious
disease. If you do have these
symptoms, see your physician
for a proper diagnosis.
1. chronic cough
2. repeated bouts of pneumonia
or bronchitis
3. hoarseness
4. weight loss/loss of appetite
5. shortness of breath
6. wheezing
7. chest pain
8. coughing up blood
> Risk factors for lung cancer
include tobacco use, secondhand
smoke, personal and family history, gender, and cancer-causing
agents such as arsenic, asbestos,
or radon.

This information was excerpted from several sources, including the American Cancer Society
and the American Lung Association. If you would like to read more about lung cancer, check
out the following web sites:
American Cancer Society—www.cancer.org
Alliance for Lung Cancer, Advocacy, Support & Education—www.alcase.org
American Lung Association—www.lungusa.org
American Medical Association—www.ama-assn.org
National Cancer Institute—www.nci.nih.gov
National Heart, Lung, and Blood Institute—www.nhlbi.nih.gov/index.htm
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Clips // Coils
High-volume centers show results in treatment of 5AH

CAN BE A VIOLENT ASSAILANT. TYPICALLY
CAUSED BY A RUPTURED ANEURYSM-A WEAK SPOT IN A BRAIN BLOOD VESSEL THAT BLEEDS INTO THE SPACE
BETWEEN THE BRAIN AND SKULL-SAH AFFECTS THOUSANDS OF AMERICANS EACH YEAR AND,

IN MANY CASES

RESULTS IN DEATH OR PERMANENT BRAIN OR NERVE DAMAGE.

A LARGE-SCALE STUDY LED BY DEWITTE CROSS, MD, ASSOCIATE PROFESSOR OF RADIOLOGY, OFFERS NEW HOPE T
PATIENTS WITH SAH, ESPECIALLY THOSE LIVING NEAR "HIGH-VOLUME" MEDICAL CENTERS. AS IS TRUE WITH MAN
TYPES OF MEDICAL AND SURGICAL

:E MORE SAH CASES TREATED AT A FACILITY, THE BETTER THE

OUTCOMES TEND TO BE. BUT CROSS,
INSTITUTE OF RADIOLOGY, AND THE MULTIDISCIPLINA
MENT IN SAH-RELATED MORTALITY RATES BETWEEN HIGH-VOL

iTERVENTIONAL NEURORADIOLOGY AT MALLINCKRODT
EAM WERE STRUCK BY THE DRAMATIC IMPROVELOW-VOLUME CENTERS.

'.»!

Study results
In a retrospective study of
more than 16,000 hospital admissions for SAH in 18 states, the
researchers concluded that
hospitals treating more than 35
SAH cases per year had a 40 percent lower mortality rate than
did those hospitals treating less
than 10 cases. And this is good
news for St. Louis area-residents:
Barnes-Jewish Hospital at Washington University Medical Center
ranks among the high-volume
centers, with about 150 admissions for SAH per year and about
200 patients with ruptured and
unruptured cerebral aneurysms
treated annually.

Specific causative factors
could not be identified by the study
data, but Cross believes several
factors found at high-volume
centers contribute to the improved
SAH mortality rates.
♦ Large tertiary centers such as
Barnes-Jewish Hospital offer a
wider array of both surgical and
noninvasive techniques and
strategies.
♦ The centers have experienced
neurosurgeons, interventional
radiologists, and support staff.
♦ Physicians have access to the
latest advances in diagnostic
and treatment technology.

According to Cross,
Washington University Medica
Center has another advantage:
a tremendous level of interdepartmental cooperation. And
this is extremely important in
cases, such as SAH, where
there are two possible treatme
options—one surgical, the
other endovascular.

The Cerebral Aneurysm Treatment Team: (left
right) doctors Christopher Moran, DeWitte Cri
and Colin Derdeyn—neuroradiology; Ralph D(
Robert Grubb, and Michael Chicoine—neurolo
surgery. Not shown are doctors Keith Rich, C
gory Zipfel, and Joshua Dowling—neurologic
surgery; and Michael Diringer and Venkatesh
Aiyagari—neurology; and Tracy Dobbie, RN.
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Causes of SAH
Initially, there are two types of
SAH cases: traumatic and spontaneous. Traumatic SAH is caused
by an injury—in the United States,
mostly from bicycle, motorcycle,
or automobile accidents. According to the Brain Injury Association,
approximately 373,000 people
are hospitalized annually with
brain injuries.
Spontaneous SAH is usually
caused by the rupturing of an
aneurysm and occurs most frequently in people between the ages
of 35 years to 65 years. Weakening
of the vessel wall can occur even in
healthy people, but some common
risk factors include smoking, high
blood pressure, head trauma, and
alcohol abuse. About two million
Americans have brain aneurysms,
and most of these aneurysms
remain undetected and cause no
harm. However, statistics show
there are about 30,000 ruptured
aneurysms every year in the United
States. About half of those cases
result in death caused by the sudden increase in pressure on the
brain, resulting from the flow of
Colorized 3D angiogrophic renderings of an anterior
communicating aneurysm.
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blood into the subarachnoid space.
The pressure cuts off blood supply
to the brain.
SAH survivors face a troubling
prognosis: a recurrence of bleeding
or other complications (resulting in
a 50 percent mortality rate) or
debilitating impairments affecting
motor skills, vision, speech, or
mental function. But these grim
outcomes are dramatically
improved if SAH, and the culprit
aneurysm, can be diagnosed and
treated quickly.

Treatment options
At Washington University Medical Center, patients with suspected
SAH typically come first to the
Charles F. Knight Emergency Center. Patients describe the headache
pain typical of the SAH attack as
the worst pain they have ever experienced. They may also suffer disorientation, vomiting, and loss of
consciousness. Patients are evaluated immediately either by a computed tomography (CT) scan or
spinal tap to confirm the SAH, then
by a cerebral angiogram to locate
the aneurysm.

The next step involves the joint
effort of interventional neuroradiologists and neurosurgeons like
Cross and Ralph Dacey, MD,
professor of neurosurgery and
chairman of the medical school's
Department of Neurological
Surgery. Here the interplay of
experience, access to and knowledge of the latest technology, and
cooperation among disciplines
work to determine the best course
of action— surgical or noninvasive.
Surgeons can perform a clip litigation (opening the skull and using a
clip to close the offending
aneurysm); interventional neuroradiologists can use a catheter and
special metal coils to close the
aneurysm.

The importance
of teamwork
Cross explains the importance
of teamwork at Washington University Medical Center: "One of our
strengths in this field is our joint
approach to SAH treatment, with
the sole concern of what is best for
the patient. Some patients are not
candidates for noninvasive treatment, and surgery is the best
option. But we have to act
quickly—the sooner the bleeding
is controlled, the less likely the
chance of recurrence."
To decide which option is
appropriate for a particular patient,
the team evaluates four factors:
location of the aneurysm, its
shape, the clinical grade of the
patient, and patient preference
(if the patient is conscious
and able to participate in the
treatment choice). To date,
about half of the SAH cases
have been treated surgically.

MALLINCKRODT INSTITUTE OF RADIOLOGY

A

1

esource

A noninvasive choice
The remaining 50 percent of
cases have undergone endovascular
coil embolization, a relatively new
and minimally invasive radiology
procedure benefiting from
advances in microcatheter technology. Endovascular coil embolization uses tiny tubes inside arteries
(microcatheters) to enter and treat
the aneurysms. To treat SAH, the
patient undergoes general anesthesia. A neuroradiologist threads a
catheter through the femoral artery
in the groin, making a small incision
at the insertion site. This thin tube
is maneuvered directly into the site
of the ruptured aneurysm, using
angiography during the procedure
to guide the catheter. Angiography
uses an injected contrast, which
flows into the arteries, mapping the
blood flow out of the rupture.
"These 'maps' are made even
clearer by the use of advanced
angiography, which gives us biplanar images during the procedure,"
says Cross. "I can see the catheter,
the aneurysm, and the artery
in several relational views as I
am working."

THE FOLLOWING LISTING DOES NOT IMPLY MALLINCKRODT
INSTITUTE'S ENDORSEMENT OF THESE WEB SITES' CONTENT
BUT IS INTENDED SOLELY FOR GUIDANCE ON WHERE TO BEGIN
YOUR SEARCH FOR SAH INFORMATION.
AMERICAN SOCIETY OF NEUR0RADI0L0GY (WWW.ASNR.ORG)
AMERICAN ASSOCIATION OF NEUROLOGICAL SURGEONS
(WWW.AANS.ORG)
AMERICAN SOCIETY OF INTERVENTIONAL AND THERAPEUTIC
NEUR0RADI0L0GY (WWW.ASITN.ORG)
BRAIN INJURY ASSOCIATION (WWW.BIAUSA.ORG)
BRAIN INJURY ASSOCIATION OF MISSOURI
(WWW.BIAUSA.ORG/MISS0URI/BIA.HTM)

1

rj
Ralph Dacey, MD, (right) and a neurological
surgery team
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DEWITTE CROSS, MD
RALPH DACEY, MD
COLIN DERDEYN, MD
CHRISTOPHER M0RAN, MD
DAVID TIRSCHWELL, MD
BOSTON SCIENTIFIC CORPORATION
MARY ANN CLARK, MHA
DANIEL TUDEN,
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cerebral aneurysm
before and after
clipping.
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(C and D) Anterior com-
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municating aneurysm
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before and after coiling.
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Next, tiny platinum coils are fed
into the rupture to block the flow of
blood. Platinum is used because the
material does not interfere with the
magnetic forces used in many imaging procedures, such as magnetic
resonance imaging. Coils range in
size from two to 20 millimeters in
diameter and come in many shapes.
They are inserted into the catheter
as straight sections and curl up into
their initial shape when deployed,
then they are detached in the
Interventional Neuroradiologist DeWitte Cross
prepares to insert an arterial catheter, to begin
an endovascular aneurysm treatment procedure.
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aneurysm using a minute jolt of
electrical current. Imagine
stretching a Slinky® (the wire toy
that's been around since 1945) until
it is straight, then letting it go— that
is a platinum coil, enlarged many
times over.
Cross explains the finesse
involved in this procedure: First, a
'basket' with a complex coil shape is
created within the aneurysm; then,
helical-shaped coils are placed
inside until the bleeding is controlled. "That's another advantage of
being a high-volume treatment center, we have a large supply of various coil shapes and sizes," he says.
When the neuroradiologist is
satisfied with the coil arrangement,
the catheter is withdrawn and the
small incision is sutured. The
patient is taken to the hospital's
Intensive Care Unit to be monitored for at least 24 hours and may
be ready to return home as early as
the next day in electively treated
cases, while patients with SAH
remain in the hospital longer for
full recovery. With the surgical
treatment, a longer hospital stay
and significantly longer time to full
recovery is required for elective
aneurysm treatment.
Cross emphasizes that coils are
not appropriate in every case. The
re-treatment rate following the
coils procedure is 10 percent, as
compared to two percent for surgical clipping—so aneurysms that
can be treated surgically with low
rates of morbidity are often

clipped. However, there are advantages to the coil procedure in
aneurysms that are difficult to treat
surgically, including lower risks of
permanent disability and lower
mortality. The British medical journal Lancet reported in a 2002 multicenter study, mainly of anterior
communicating aneurysms, that
coiling resulted in a 22.6 percent
reduction in the relative risk of disability or death over the neurosurgical clipping procedure.

21st century training
MIR's interventional neuroradiology fellowship program is training the next generation of
specialists who will learn even better techniques and procedures.
Equally important, says Cross, is
that these trainees learn the importance of cooperation among disciplines and cross-specialization in
their own careers. "We are a highvolume medical facility in part
because of our advanced technology," he explains. "But our physicians and staff and the
long-standing reputation of colleagues such as Doctor Dacey are
what continue to bring surgical
and radiology referrals to Washington University Medical Center.
And, ultimately, that equates to
lives saved." mm
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fl NEW STUDV HT MflLLINCKRODT
INSTITUTE USES 11C-ACETATE AND

Tracking Elusiue
Prostate Cancer

PET TO DETERMINE TREATMENT FOR
PATIENTS UJITH PROSTATE CANCEA.

medicine on sophisticated computer
applications such as reconstruction
orithms and display techniques for
hree-dimensional data, Tom Miller, professor of radiology and of
biomedical engineering,
had seen this young field
cessing reach successful
maturity, in part through his own pioneering efforts.

In 1997, he was ready

for a neuj challenge that mould combine
physics and nuclear medicine. But, ujhat
should it be?

by

Candace

O'Connor

H
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I kind of stuck my head
out of the door of my
office and heard this
swish-swish-swish
sound," he says, moving
his head from side-to-side. "PET,
PET, PET [positron emission tomography]. PET tumor imaging, PET
oncology. You hear 'PET' echoing
up and down the halls of Mallinckrodt Institute at a deafening pitch.
It didn't take a genius to figure out
what I was going to do."
So Miller decided to re-tool his
career and focus on tumor-imaging
research with PET, a technology
developed at Mallinckrodt Institute
of Radiology (MIR) in the 1970s.
Soon that new interest led Miller to a

study of cervical cancer using PET and
18F-FDG, a radiopharmaceutical effective in tumor imaging.
More recently, Miller's interest has
resulted in two important studies of
prostate cancer, the most commonly
diagnosed cancer in men in the United
States and the second-leading cause of
cancer deaths in men over age 40. In a
pilot study, now completed, Miller and
a group of collaborators looked at the
effectiveness of HC-acetate, another
radiopharmaceutical used in PET imaging, to diagnose recurrent prostate cancer. In a second study, still ongoing,
investigators are testing whether PET
and HC-acetate can reliably determine
the full extent of cancer present in
high-risk patients who were recently
diagnosed with prostate cancer.

Nuclear Medicine Physician Tom Miller earned a PhD degree in nuclear physics from Stanford University and an
MD from the University of Missouri-Columbia. Prior to joining the MIR faculty in 1981, he completed a
residency at the Institute.
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"Although prostate cancer is a
major problem, we lack good imaging
methods to detect the disease," says
Miller. "That is what we are addressing here: If we can find cancer metastasis that is missed by conventional
imaging methods at the time of diagnosis, that discovery could lead to a
major alteration in treatment for these
patients. So we will have a big payoff
if this method works."

Prostate cancer
screening
Diagnosing prostate cancer in its
early stages used to be problematic—until William Catalona,
MD, former head of the Division of
Urologic Surgery at Washington
University in St. Louis School of
Medicine (WUSM), pioneered the
prostate-specific antigen (PSA) test in
the early 1990s. Widespread PSA
screening has since led to the much
earlier diagnosis of prostate cancer.
Screening
works this way:
When a man's PSA
level is elevated,
prostate cancer may
be present, and a
biopsy is performed
for confirmation. If
that test is positive,
the next step is to
determine how the
disease should be
treated. Younger
men with localized
cancer often

MALLINCKRODT INSTITUTE OF RADIOLOGY
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undergo a radical prostatectomy;
older men for whom surgery would
be risky have primary treatment of
radiation therapy.
The situation becomes more
complicated when the cancer has
spread beyond the prostate gland.
For these patients, surgery would no
longer provide a cure; instead, they
may need systemic hormone therapy.
Thus, if physicians know the cancer
has metastasized, patients can avoid
a risky surgical procedure, which
would provide no benefit and has
associated adverse effects, or a long
course of radiation therapy.
However, it is sometimes difficult to tell whether a newly diagnosed patient has disease in the
lymph nodes or in more distant sites.
As part of the diagnostic exam, this
patient should have a bone scan and
an initial computed tomography (CT)
scan to check if the disease has
spread. Often, especially if the man's
PSA level was relatively low, these
tests show negative results; however,
in some cases, these results may be
misleading.

PET's role in detecting
hidden cancer
I hile prostate cancer is genI erally a slow-growing dismJU ease, about 20 percent of
patients—even those diagnosed
through regular PSA testing—have a
high-grade form of cancer with a
more aggressive course. Recently,
Mallinckrodt Institute physicians
began providing radiologic services
to the Veterans Administration (VA)
Hospital in St. Louis. For reasons
unclear at present, diagnostic testing
is showing a higher-than-normal
proportion of these veterans with
high-grade prostate cancer.
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Such patients are
more likely to have hidden
Biopsy proven prostate recurrence
disease at the time of diagfollowing RT
nosis, although their initial
workup and tests show
nothing suspicious. "It's
difficult to find," says
Miller. "We're studying
whether the lymph nodes
can be detected when the
CT results are already
negative, but we are limiting our study to cases in
which PET imaging could
really make a difference."
PET is a potentially
useful tool. Already, the
combination of PET and
18F-FDG has proven
effective in detecting
many other forms of cancer, including lung, lymWith 1 IC-acetate, lymph with tumor (n)
phoma, colon, breast, melanoma,
and prostate recurrence (p) is clearly indicated.
esophagus, liver, cervical, and recurWith FDG, result is negative for both tumor
rent brain cancer. But FDG usually is
and recurrence.
not effective in detecting prostate
cancer, probably because FDG is a
sugar, an analog of glucose; prostate
cancer has a low demand for energy
since it grows so slowly.
Finding a new, more effective
radiopharmaceutical to use with
PET was a key need. Miller's study
of cervical cancer with FDG was
underway when a preliminary
abstract in a medical journal
reported that HC-acetate PET
seemed promising in detecting
prostate cancer.
Miller, who had worked on computer imaging with HC-acetate in
measuring myocardial oxidative
metabolism, was familiar with this
agent. Better still, HC-acetate,
which has an extremely short half-life
of around 20 minutes, was already
being produced in the Institute's
radiological chemistry laboratory
for use in cardiac studies. Further,
the urologic surgery staff at
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Barnes-Jewish Hospital could refer
prostate cancer patients, as could the
Department of Radiation Oncology's
genitourinary service.
Miller obtained two, successive
pilot grants of $25,000 each from Siteman Cancer Center as well as a grant
from the CaPCure Foundation to
compare the effectiveness of 18FFDG PET and HC-acetate PET in
patients who had undergone radical
prostatectomy or radiation therapy
and subsequently developed a rising
PSA level—indicating a likely disease
recurrence. Some 30 percent of
these men will have local recurrences, while 70 percent will have
distant disease with or without
local recurrence.
In comparative studies of 46
patients using both radiopharmaceuticals—(30 men initially were treated
with surgery; 16, with primary radiation)—investigators found that
among those patients whose disease
was confirmed by CT scan or biopsy,
30 percent were identified by 11C-

Miller has now received
National Institutes of Health
(NTH) funding to continue
investigating HC-acetate PET. Over
a five-year period, the research team
plans to accrue 200 to 300 newly
diagnosed, high-risk patients who
have a PSA level of 10 or greater, a
Gleason (biopsy) score of at least
seven, and bone and CT scans negative for metastasis. Unlike patients
whose initial PSA level is lower, men
in this group are more likely to have
cancer that has spread outside the
prostate and has not shown up
during the diagnostic workup.
"Despite intensive PSA screening, about ten percent to twenty
percent of newly diagnosed cancer
patients have advanced tumors,"

Pilot Grants Collaborators

R lilelcome Rdditior

Nuclear Medicine
Keith Fischer, MD
Tom Miller, MD, PhD
Barry Siegel, MD

Jerald Andriole, MD

'am Kibel, MD

Medical Oncology

acetate PET, while only 9 percent
were identified by 18F-FDG PET.
Clearly, HC-acetate PET was the
much superior tool.

Current Study

PhD,
a urologist on sabbatical from
Japan's Fukui University,
who was working in Welch's
laboratory. (Oyama, who had
worked with 11 C-acetate PET
in Japan, not only .wrote a
grant proposal that resulted in
additional funding from the
CaPCure Foundation but also
was first author on a paper
published in 2003 in the
Journal of Nuclear Medicine.)

says Gerald Andriole, MD, chief of
WUSM's Division of Urologic
Surgery. "There is an urgent need to
identify these patients prior to treatment. Carbon eleven-acetate scanning may be useful for these patients,
as well as for men with recurrence
after surgery or radiation therapy.
If we are able to more precisely
stage such patients, we can optimize
their treatments."
Specifically, says Adam Kibel,
MD, director of urologic oncology,
"if we could identify those high-risk
patients showing metastasis, they
could be spared the morbidity of
unnecessary surgery or radiation
therapy. Also, high-risk patients
whom we previously would not treat
with curative intent now could be
diagnosed as free of metastasis, and
we could try to cure them."
There should be no problem
recruiting enough patients, since the
surgeons and radiation oncologists at
Washington University Medical
Center annually treat approximately
800 patients newly diagnosed with
prostate cancer. The high-risk
patients at the VA Hospital should
provide another pool of patients,
and the researchers also plan to
contact some community urologists
for referrals.
So far, eight men with newly
diagnosed prostate cancer have been
tested, using the medical center's
combined PET/CT scanner. Cary
Siegel, MD, an associate professor of
radiology with CT expertise, is interpreting the patients' CT scans, while
the study's nuclear medicine physicians are interpreting the PET scans.

Radiation Oncology
Radiological Sciences
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Results to date have been
encouraging. Among the study's
eight patients, two men have shown
evidence of cancer metastasis that
was not apparent on the bone scan or
on the CT scan. In one patient, the
cancer had spread to a tiny lymph
node near the prostate. The PET scan
of the other patient showed affected
lymph nodes in the abdomen and in
the neck, with the neck node confirmed by ultrasound-guided biopsy.
"Unfortunately, this patient has
documented metastatic cancer," says
Jeff Michalski, MD, chief of Radiation
Oncology's genitourinary service,
"but because the metastasis was
detected, he has avoided a long
regimen of expensive, unnecessary
radiation therapy that would not have
provided any benefit. He is receiving
hormone therapy, a dramatic change
in his care."
With many more patients to be
enrolled in the study, Miller and his
colleagues are cautiously optimistic
about HC-acetate
PET as an important
prostate cancer tool.
This radiopharmaceutical does have
some inherent limitations: primarily, a
20-minute half-life
that, unlike the 110minute half-life of
18F-FDG, limits its
use to an institution
with an in-house
cyclotron. [Editor's
note: Mallinckrodt
Institute currently
has two in-house
cyclotrons and was
the first medical
facility in the
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United States to have a dedicated
cyclotron.] MTR's radiological chemistry laboratory, headed by Michael
Welch, PhD, is currently performing
animal studies with a new radiopharmaceutical, 18F-Fluoroacetate, which
has the advantages of 1 lC-acetate
plus a nearly two-hour half-life.
Will patients with a positive PET
scan have a worse long-term outcome than those patients whose PET
scan was negative? There is currentiy
no definitive answer to this question.
But patients who participated in
Miller's study will have follow-up
care over several years, and their
information could help change
prostate cancer treatment and patient
outcome. "If the study goes well,"
says Miller, "PET with carbon elevenacetate could become a routine
clinical test for men with a high-risk,
new diagnosis of prostate cancer."
If this study's conclusions are as
hoped for, adds Michalski, "we will
be better able to tailor treatment to

those patients who are likely to benefit from it, to avoid the morbidity and
toxicity for patients who will not
benefit from treatment, to avoid
unnecessary surgeries if patients
have evidence of metastasis, and to
identify a group of patients who
require therapy that is either more
aggressive or more innovative than
what we have been able to provide."
Editor's Note: Urologists who wish
to refer patients to the HC-acetate
PET study or would like more information about the use of this test in
the clinical setting may contact the
study coordinators, Jennifer Frye
and Helen Kaemmerer, at (314)
362-7021. EH

Jeff Michalski, MD, also serves as director of
the Clinical Division in the Department of
Radiation Oncology.
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In this section, the names of employees who are full-time
faculty or staff or who have an appointment in the
Department of Radiology or Department of Radiation
Oncology are highlighted in boldface type.

NEW FACULTY
Michael Penney, MD,
instructor in radiology,
Division of Diagnostic Radiology (at Barnes Jewish
St. Peters Hospital), Department of Radiology.
Robert Steiner, MD,
instructor in professor,
Division of Diagnostic Radiology (at Barnes-Jewish
St. Peters Hospital), Department of Radiology.

GRANTS
Samuel Achilefu, PhD,
associate professor of radiology, as principal investigator, received a $153,000
grant from the National
Institutes of Health for
research on "Novel
monomolecular multimodality imaging agents. Coinvestigators for the one-year
award are Michael, Welch,
PhD, professor of radiology,
of chemistry, and of molecular biology and pharmacology; Barry Siegel, MD,
professor of radiology and
ofg medicine; Gregory Lanza,
MD, assistant professor of
medicine; Samuel Wickline,
MD, professor of medicine;
and Brinton Chance, MD,
University of Pennsylvania.
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Kevin Black, MD, assistant
professor, of psychiatry, of
neurology, and of radiology,
as site principal investigator,
received a grant from the
National Institute of Neurological Disorders for
research on "Serotonergic
antidepressant in Parkinson's disease." As site
principal investigator, he
also received a one-year
grant from ACADIA Pharmaceuticals for "Phase 2,
multi-center, placebo controlled, double blind trial of
ACP-103 in the treatment
of psychosis in Parkinson's
disease (Clinical protocol #
ACP-103-006)."
Thomas Conturo, MD,
PhD, associate professor
of radiology and adjunct
professor of physics and
biomedical engineering, as
principal investigator,
received a one-year grant of
$56,390 from Sun Microsystems, Inc. for research on
"Computational hardware
for MRI research and development." As principal investigator, he also received a
one-year grant of $8,000
from Mallinckrodt, Inc/Tyco
Healthcare, Inc. to study
"MRI compatibility of patient
accessories in phantoms and
animals."
Robert Gropler, MD,
professor of radiology, of
medicine, and of biomedical
engineering, as principal
investigator, received a
$3.7 million grant from the
National Institutes of Health,
for research on "Altered
myocardial fatty acid metab-

olism in obesity." Coinvestigators for the five-year
award are Pilar Herrero, MS,
research scientist in radiology; Samuel Klein, MD,
professor of medicine; and
Linda Peterson, MD, assistant professor of medicine.
Joel Perlmutter, MD,
professor of neurology,
of neurological surgery, of
radiology, and of physical
therapy, as principal investigator, received a $1.9 million
grant from the National Institutes of Health (NIH) and a
$25,000 fellowship grant
from Medtronic, Inc. for
research on "Mechanisms
of deep brain stimulation."
Theodore Cicero, PhD, vice
chancellor for research, as
principal investigator, and
Perlmutter, as co-principal
investigator, received a $1.8
million award from NIH for
renovations needed to complete a 14,000 square feet,
neuroclinical research unit.
Joshua Shimony, MD,
PhD, assistant professor of
radiology, as principal investigator, received a two-year
grant of $80,000 from the
McDonnell Center for the
Studies of Higher Brain
Function for research on
."Mapping neuronal connectivity in the human visual
cortex and in the frontalparietal region."
Marilyn Siegel, MD, professor of radiology and of
pediatrics, received a oneyear grant of $5,000 from
the Society for Pediatric
Radiology for research on
"Measurements of epicardial
and visceral fat: correlation
with treatment options."

APPOINTMENTS/
ELECTIONS
Carolyn Anderson, PhD,
associate professor of radiology, was elected to a twoyear term as secretary/
treasurer of the Society
for Radiopharmaceutical
Chemistry and Biology.
Colin Derdeyn, MD,
associate professor of
radiology, was appointed as
a consultant to the Neurological Devices Panel of the
Medical Devices Advisory
Committee for the Food
and Drug Administration's
Center for Devices and
Radiological Health.
Jay Heiken, MD, professor
of radiology, was appointed
to a one-year term on the
American College of Radiology Imaging Network
Gastrointestinal Disease
Site Committee.
Susan Langhorst, PhD,
CHP, assistant professor of
radiology, was appointed to
a two-year term as a member
of the National Academies of
Science Board on Radioactive Waste Management.
Linda Larson-Prior, PhD,
research associate professor
of radiology, was elected
treasurer of the Executive
Board of the Organization
for Computational Neuroscience.
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obert McKinstry, MD,
hD, assistant professor of
adiology, was appointed to
seven-year term as chairlan of the Neuroradiology
ommittee and as a member
f the Executive Committee
if the Silent Cerebral Infarct
vlulticenter Trial, funded by
ihe National Institute of
Neurological Disorders.
He was appointed codirector
of the Mallinckrodt Institute
Research Residency Training
Program.
Eduardo Moros, PhD,
associate professor of radiation oncology, was elected to
a four-year term as president
of the International Association for Hyperthermic
Oncology, the international
organization representing
the North American Hyperthermia Society (NAHS),
the European Society for
Hyperthermic Oncology,
and the Asian Society for
Hyperthermic Oncology.
He also was elected to a oneyear term (2004-2005) as
president of NAHS.
Bradley Schlaggar, MD,
PhD, assistant professor
of neurology, of radiology,
of pediatrics, and of anatomy
and neurobiology, was
appointed consulting editor
for the journal Developmental Psychology.
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Biello Lecture
Former MIR faculty member, Landis Griffeth, MD,
PhD, presented the Eighteenth Annual Daniel R.
Biello Memorial Lecture on
March 8. Griffeth, director
of nuclear medicine in the
Department of Radiology at
Baylor University Medical
Center (Texas), presented
"Lymphoma: a model
for PET's role hi cancer
management."
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Griffeth (left) is shown with Barry Siegel, MD chief, Division of Nuclear Medicine, and coordinator of the
Biello Lecture.

Barry Siegel, MD, professor of radiology and of
medicine, was elected to a
three-year term as a member-at-large of the Academy
of Molecular Imaging Board
of Directors.
Marilyn Siegel, MD, professor of radiology and of
pediatrics, was appointed
as a consultant to the Food
and Drug Administration
for pediatric cardiac and
extracardiac vascular
imaging using computed
tomography and magnetic
resonance angiography.

Bruce Whiting, PhD,
research professor of radiology, was elected as the 2004
chairman of the St. Louis
Chapter of the Engineering
in Medicine and Biology
Society of the Institute of
Electrical and Electronics
Engineers.
Pamela Woodard, MD,
assistant professor of
radiology, was elected to a
two-year term as secretarytreasurer of the North
American Society of
Cardiac Imaging.

HONORS/
AWARDS
Thomas Conturo, MD,
PhD, associate professor
of radiology and adjunct professor of physics and biomedical engineering, was
invited to serve as guest
editor of the Journal of
Magnetic Resonance Imaging's special issue on
"Quantitative cerebral
perfusion imaging using MRI:
a technical perspective."
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Robert Malyapa, MD, PhD,
assistant professor of radiation oncology, received the
Radiation Therapy Oncology
Group's (RTOG's) Simon
Kramer New Investigator
Award for his research project "Oncologic imaging of
tumor hypoxia and correlating findings on Cu-ATSM
PET scans to cellular markers that may predict for radiation response." The award
was presented in January at
the RTOG Winter SemiAnnual Meeting in New
Orleans, Louisiana.
Stephen Moerlein, PhD,
associate professor of radiology and of biological chemistry, and Yuan-Chuan Tai,
PhD, assistant professor of
radiology, received the
Image of the Year Award for
their research on "Quantitative neuroreceptor imaging
of transgenic mice" at the
Concorde Microsystems Inc.
Users Meeting in March.
Douglas Rowland, PhD,
research instructor of radiology, received the Best Dramatic Dynamic Image of the
Year Award at the Concorde
Microsystems Inc. Users
Meeting in March. Rowland; Richard Laforest,
PhD, assistant professor of
radiology; Yaun-Chuan Tai,
PhD, assistant professor of
radiology; and Michael
Welch, PhD, professor of
radiology, of chemistry, and
of molecular biology and
pharmacology, used the
microPET scanner to produce the award-winning
gated cardiac images.
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LECTURES
Carolyn Anderson, PhD,
associate professor of radiology, presented "Copper-64labeled biomolecules for
tumor targeting" at
Lawrence Berkeley Laboratory, Berkeley, California,
January 28.
Sanjeev Bhalla, MD, assistant professor of radiology,
as invited speaker, presented
"Finding blue pearls: Eastern
reflections on Western medicine" at the 51sl Annual Alpha
Omega Alpha Lecture,
Washington University in
St. Louis, Missouri, April 6.
Kevin Black, MD, assistant
professor of psychiatry, of
neurology, and of radiology,
spoke on "Neuroimaging
studies of dopaminergic
function in Tourette Syndrome" at the Tourette Syndrome Association Young
Investigators Symposium,
Atlanta, Georgia, January 31.
Jeffrey Bradley, MD, assistant professor of radiation
oncology, presented "Dose
response and complications"
at the Optimizing of Thoracic
Irradiation: RTOG Symposium, sponsored by the Radiation Therapy Oncology
Group, New Orleans,
Louisiana, January 16. He
spoke on "Current issues in
conformal radiotherapy for

lung cancer: targeting
tumors with FDG-PET" at
the National Institutes of
Health/National Cancer Institute, Bethesda, Maryland,
March 31 and April 1. He presented "Radiation treatment
planning with PET/CT" at
the CMS Users Meeting, St.
Louis, Missouri, April 25.
Jeffrey Brown, MD, associate professor of radiology,
presented "Diagnosis and
staging of cholangiocarcinoma and gallbladder
cancer by MRI" at the 12th
Annual WUSM Refresher
Course and Update in General Surgery, St. Louis, Missouri, February 26.
Thomas Conturo, MD,
PhD, associate professor of
radiology and adjunct professor of physics and biomedical engineering, spoke
on "Research and development of dynamic susceptibility contrast perfusion MRI
for neurological studies" and
"Beyond the tensor: measurement of displacement
probabilities and other diffusion parameters in tissues"
at the Symposium on
Advanced Magnetic Resonance Imaging in Neuroscience, Istituto Nazionale
•Neurologico "Carlo Besta,"
Milan, Italy, March 24.

Maurizio Corbetta, MD,
associate professor of neurology and of radiology, presented "The attention system
of the human brain" to the
Department of Neuroscience, Medical College of
Wisconsin, Milwaukee, January 21. He spoke on "A strategy to investigate recovery
of cognitive functions with
functional brain imaging" at
the International Symposium
on Neuroimaging of Stroke
Recovery, Columbia University, New York City, New
York, February 2 and 3. He
spoke on "Brain systems for
the control of perception
and action" at the Neuroscience Colloquium, sponsored by the French National
Center for Scientific
Research (CNRS), Lyons,
France, February 6. Corbetta
presented "From neurology
to neuroscience: brain imaging studies of visual attention in the normal and
damaged brain" at Brain Sciences Lectures, University of
Chieti, Italy, February 10. He
presented "Stroke recovery:
a neuroimaging approach" at
the Clinical Neuroscience
Grand Round, Fatebenefratelli Hospital, Rome, Italy.
February 12. Corbetta spoke
on "Brain imaging studies of
neurological recovery in
brain and spinal cord injury
at the Clinical Neurosciencr
Grand Round, Southwesten
Medical University, Dallas,
Texas, March 3. He presented "The influence of
action on visual cortex" at
the International Conference
on New Perspective in
Vision, Isle of Mull, Scotlan ,
April 14-16.
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,olin Derdeyn, MD, assoiate professor of radiology,
iresented "Role of cerebral
lemodynamics in ischemic
troke" and "Treatment of
arotid atherosclerotic disease: medicine, surgery, or
tent" at the Colorado Radioogical Society meeting, Denver, January 15. He spoke on
A patient with complete
carotid occlusion" at the
St. Louis Vascular Surgery
29* Annual Meeting,
St. Louis, Missouri, January
19. Derdeyn spoke on
"Management of posterior
circulation aneurysms" and
"Selection of patients for

cerebral revascularization:
the role of hemodynamic
assessment" at the 7th Annual
Joint Meeting of the American Association of Neurological Surgeons/Congress of
Neurological Surgeons Joint
Section on Cerebrovascular
Disease and the American
Society of Interventional and
Therapeutic Neuroradiology,
San Diego, California, February 2 and 3. He presented
"The carotid occlusion
surgery study" at Medical
Grand Rounds, Alton Memorial Hospital, Alton, Illinois,
February 18.

Cardiovascular MR Course
Twenty participants attended the 6th annual "Cardiovascular MR Course: Hands-on Experience," held in
the Institute's East Building on January 20-22. Course
faculty: Pamela Woodard, MD, course director;
Glenn Foster, RT; Robert Gropler, MD; Fernando
Gutierrez, MD; Richard Nagel, RT; Vamsidhar
Narra, MD; Orlando Simonetti, PhD (Northwestern
University); and Gary McNeal (Northwestern University and Siemens Medical Systems).
For more information about this course, call (314)
747-3878.
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Steven Don, MD, associate
professor of radiology,
spoke on "Radiosensitivity
of children: potential for
overexposure in CR and
DR and magnitude of doses
in ordinary radiographic
examinations" at the ALARA
Concept in Pediatric CR
and DR, Houston, Texas,
February 28.
Louis Gilula, MD, professor of radiology, of
orthopaedic surgery, and
of plastic and reconstructive
surgery, presented "Vertebroplasty in fractures with
spinal cord impingement"
at the Society of Skeletal
Radiology, Tucson, Arizona,
March 9. As visiting professor, he spoke on "Cervical
spine trauma" at the Oregon
Health and Science University, Portland, April 15.
Perry Grigsby, MD, professor of radiation oncology
and of radiology, spoke on
"Radiation therapy for cancer of the thyroid," "Multimodality management of
cancer of the cervix," and
"Treatment of endometrial
cancer" at the 56th Annual
Midwinter Radiation Oncology Conference, Los Angeles, California, January
23-25. He presented "New
imaging techniques" at the
35th Annual Meeting of the
Society of Gynecologic
Oncologists, San Diego,
California, February 9-11.

Jay Heiken, MD, professor
of radiology, presented "CT
colonography: technique,
results and future directions"; "MDCT evaluation of
small bowel obstruction";
"Characterization of hepatic
masses with helical CT"; and
"CT of the abdominal aorta:
aneurysm rupture and postoperative complications" at
Computed Body Tomography 2004: the Cutting Edge,
sponsored by Johns Hopkins
University, Orlando, Florida,
February 12-15. He moderated a session on "Imaging of
acute abdominal conditions"
and spoke on "Imaging small
bowel obstruction" at ARC
2004 Abdominal Radiology,
presented by the Society of
Gastrointestinal Radiologists
and the Society of Uroradiology, Scottsdale, Arizona,
March 7-12. He spoke on
"Contrast medium administration and scan timing for
MDCT" and "Aortic stent
grafts: pre-operative and
post-operative evaluation
with MDCT" at New
Advances in Non-Invasive
Vascular Imaging 2004,
San Francisco, California,
April 3.
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Charles Hildebolt, DDS,
PhD, associate professor of
radiology and adjunct associate professor of anthropology, spoke on "Effect of
vitamin D and calcium on
periodontitis," "Tips on writing grant proposals," and

"The new clinical trials
program at the National
Institutes of Dental and
Craniofacial Research" at the
Southern Illinois University
School of Dental Medicine,
Alton, Illinois, April 27.

Purdy Lecture
Thomas Mackie, PhD, professor of medical physics,
human oncology, and of engineering physics at the
University of Wisconsin, Madison, was guest
speaker for the Second Annual James A. Purdy
Medical Physics Lecture on April 30. Mackie spoke
on "Tomotherapy and beyond."

Richard Laforest, PhD,
assistant professor of radiology, presented "Recent
advances in microPET imaging of rodents" at the Siteman Cancer Center
Oncologic Imaging Retreat,
St. Louis, Missouri, March
13. He presented "An introduction to the microPETFOCUS120"atthe
microPET Users meeting,
Orlando, Florida, March 27.
He spoke on "Requirements
for quantitative PET imaging" at the National Cancer
Institute Advanced Technology Symposium, April 14.

Jacob Locke, MD, assistant
professor of radiation oncology, presented "Enhancement of hyperthermic
radiosensitization with
Celecoxib: molecular targets" at the 95th Annual
Meeting of the American
Association for Cancer
Research, Orlando, Florida,
March 27-31. He presented
"Celecoxib enhances hyperthermic radiosensitization"
at the 93rd Annual Meeting of
the American Association for
Cancer Research—Radiobiology, Laguna, California,
April 6-10.

Wayne Lamoreaux, MD,
radiation oncology chief resident, presented "FDG-PET
evaluation in patients with
carcinoma of the vagina" at
the 26th International Symposium on Radioactive Isotopes in Clinical Medicine
and Research, Bad Gastein,
Austria, January 13-16.

Stephen Moerlein, PhD,
associate professor of radiology and of biological chemistry, spoke on "Preparation
of[C-ll]lS-CFTforPET
measurement of dopamine
transport activity" at the
2004 Annual Meeting of the
American Pharmacists Association, Seattle, Washington,
March 26-30.

Jason Lewis, PhD, assistant professor of radiology,
spoke on "Non-invasive measurement of hypoxia by
imaging—Cu-ATSM" at
Hypoxia: Importance in
Tumor Biology, Non-Invasive
Measurement by Imaging,
and Value of its Measurement in the Management of
Cancer Therapy, sponsored
by the National Cancer
Institute, Phoenix, Arizona,
April 7.

Eduardo Moros, PhD,
associate professor of radiation oncology, presented
"The development of systems to expose cells and
animals to electromagnetic
radiation. Engineering experience and summary to biological results" at the Joint
Graduate Program in Biomedical Engineering Spring
2004 Seminar Series, sponsored by the University of
Memphis and the Universit.
of Tennessee Health Sciem '
Center, Memphis Tennesse
March 12.

(Left to right) Marilyn Purdy; James Purdy, PhD; Mackie; and Todd
Wasserman, MD.
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"ej Pandita, PhD, assistant
professor of radiation oncol■gy, spoke on "Mammalian
rthologue of Drosphilia
[AT influences ATM func;on and embryonic development" at the EMBO
/orkshop/SS"1 Harden Conerence—Telomeres and
lenome Stability, sponsored
by The Biochemical Society,
London, England, April 3-7.
Carlos Perez, MD, professor of radiation oncology,
presented "Chemoirradiation
in locally advanced carcinoma of the uterine cervix"
and "Radiation therapy in
the treatment of carcinoma
of the uterine cervix" at
Memorial Regional Hospital,
Hollywood, Florida, February 7. He presented "Prognostic factors in early breast
cancer," "Management of
carcinoma of the rectum,"
and "Chemoirradiation for
locally advanced carcinoma
of the uterine cervix" at XXI
Renunon Nacional Medica
del Instituto, Veracruz, Mexico, February 10-14. He
spoke on "Radiopharmaceuticals in bone metastases" at
the St. Louis Society of
Medical Oncology, St. Louis,
Missouri, February 17.
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Joel Perlmutter, MD,
professor of neurology, of
neurological surgery, of radiology, and of physical therapy, spoke on "Parkinson's
disease: new pathophysiological investigations" at
Neuroscience Grand
Rounds, St. John's Mercy
Medical Center, St. Louis,
Missouri, February 18. He
presented "PET investigations of movement disorders" at the 2004 Annual
Meeting of the Academy of
Molecular Imaging, Orlando,
Florida, March 27-31.

Bradley Schlaggar, MD,
PhD, assistant professor of
neurology, of radiology, of
pediatrics, and of anatomy
and neurobiology, presented
"The developmental functional neuroanatomy of lexical processing" at the Mental
Retardation/Developmental
Disabilities Research Center,
Kennedy Krieger Institute,
Baltimore, Maryland, February 2, and at the Vanderbilt
University Institute of
Imaging Science Seminar,
Memphis, Tennessee,
February 19.

Joseph Roti Roti, PhD,
professor of radiation oncology, presented "Heat shock
effects on the DNA repair
protein MRE11 and radiosensitization by clinically relevant thermal doses" and
"Lack of biological effects
from some electromagnetic
radiations (i.e., cellular telephones) but not from others"
at Experimental Radiation
Oncology, sponsored by
The University of Texas
M.D. Anderson Cancer
Center, Houston, Texas,
February 12.

Barry Siegel, MD, professor of radiology and of medicine, presented "Clinical
applications of PET in oncology" at a meeting sponsored
by Clinical Multi-Imaging
PET-CT, Rio de Janeiro,
Brazil, January 24. He presented "Overview of PET in
oncology," "PET and lung
cancer," "Assessing response
to therapy with PET," and
"Oncologic PET: beyond
FDG" at the 4th Annual Snowbird 2004 Meeting, Clinical
Nuclear Medicine: Focus on
PET and PET/CT, Snowbird,
Utah, March 21-26. He spoke
on "PET artifacts/variants,"
"Pulmonary nodule and lung
cancer," and "PET in
women's imaging" at Clinical
Nuclear Medicine, sponsored
by Harvard Medical School,
Boston, Massachusetts,
April 27-30.

Douglas Rowland, PhD,
research instructor of radiology, spoke on "Respiratory
and cardiac gating: R4 and
focus" at the Concorde
Microsystems Inc. Users
Meeting, Orlando, Florida,
March 26.

Marilyn Siegel, MD, professor of radiology and of
pediatrics, spoke on "Pediatric CT angiography," "CT
angiography of adult mediastinal vascular anomalies,"
and "Non-coronary cardiac
CT" at the Advanced Topics
in CT Scanning: CT Angiography, 3D Imaging, Virtual
Imaging Course, sponsored
by Johns Hopkins University,
Los Angeles, California,
March 26-28, and in Baltimore, Maryland, April 2-4.
Franz Wippold, MD, associate professor of radiology,
presented "Imaging of the
herniated lumbar disk" to
the American Academy of
Orthopaedic Surgeons,
San Francisco, California,
March 10.

SYMPOSIA
In this section ofFYI, only
those faculty and staff
who have Department of
Radiology or Department
of Radiation Oncology
appointments are listed.

AMERICAN COLLEGE OF
CARDIOLOGY
53"' Annual Scientific
Session Eocposition
New Orleans, Louisiana
March 7-9, 2004
Pilar Herrero, MS,
cochair, Positron Emission
Tomography: Clinical
Studies.
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POSTER PRESENTATIONS
Pilar Herrero, MS; Joonyoung Kim, PhD; Terry
Sharp; Carmen Dence,
MS; Jason Lewis, PhD;
Robert Gropler, MD;
Michael Welch, PhD,
"Assessment of myocardial
perfusion and metabolism in
normal and diabetic rats by
microPET imaging."
Cheng Hong, MD; Pamela
Woodard, MD; Kyongtae
Bae, MD, PhD, "Assessment
of coronary artery stent
patency with in-stent contrast enhancement in multirow detector computed
tomography angiography."

ORAL PRESENTATIONS
Robert Gropler, MD, "Non
invasive imaging in the diabetic population: nuclear
cardiology, electron beam
computed tomography";
"Patients with the metabolic
syndrome have a high prevalence of left ventricular diastolic dysfunction."
Pilar Herrero, MS; Zulila
Kisrieva-Ware, MD, PhD;
Carmen Dence, MS;
Robert Gropler, MD,
"Impact of increased fatty
acid delivery on myocardial
fatty acid metabolism in
obese young women."
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INTERNATIONAL SOCIETY
FOR MAGNETIC RESONANCE IN MEDICINE
Workshop on Quantitative
Cerebral Perfusion Imaging
with MRI: A Technical
Perspective
Venice, Italy
March 21-23, 2004
Thomas Conturo, MD,
PhD, Workshop organizer;
session moderator,
"Dynamic susceptibility contrast MRI theory."

ORAL PRESENTATIONS
Erbil Akbudak, PhD;
Melanie Kotys; Dunja
Memisevic; Thomas Conturo, MD, PhD, "Quadraticity and hematocrit
dependence of Delta R2* AIF
signals at 3T: a blood phantom study under physiologic
conditions."
Erbil Akbudak, PhD;
Melanie Kotys; Thomas
Conturo, MD, PhD, "A dual
sensitivity interleaved DSC
EPI sequence for imaging
brain perfusion with AIF
sampling."
Thomas Conturo, MD,
PhD; Erbil Akbudak, PhD;
Melanie Kotys; Joanne
Markham, MS, "Arterial
input functions for dynamic
susceptibility contrast MRI:
requirements and signal
options."

Melanie Kotys; Erbil
Akbudak, PhD; Thomas
Conturo, MD, PhD, "Optimal dose determination for
Delta R2* and Delta phi
arterial input functions
using simulations."

Kyongtae Bae, MD, PhD;
Srinivasa Prasad, MD; Jay
Heiken, MD, "CT characterization of adrenal masses
using histogram analysis
method."

WORKSHOPS
POSTER PRESENTATIONS
Melanie Kotys; Erbil
Akbudak, PhD; Thomas
Conturo, MD, PhD, Effect
of signal-to-noise ratio on
signal saturation and dose
dynamic range in bolus
gadolinium Delta R2* and
Delta phi arterial input
functions."
Dunja Memisevic; Melanie
Kotys; Erbil Akbudak,
PhD; Thomas Conturo,
MD, PhD, "A blood AIF
phantom with physiologic
pulsatility, velocity, oxygenation and temperature for
gated-MRI bolus-Gd studies."

SOCIETY OF COMPUTED
BODY TOMOGRAPHY
AND MAGNETIC RESONANCE
27th Annual Course
Henderson, Nevada
March 22-26, 2004

CUM LAUDE RESEARCH
ABSTRACT AWARDS
Kyongtae Bae, MD, PhD;
Cheng Hong, MD; Srinivasa Prasad, MD; Mark
Nolte; Paul Eisenbeis; Jay
Heiken, MD, "Carbon dioxide enhanced CT imaging for
the detection of pulmonary
emboli: feasibility study in a
porcine model."

Kyongtae Bae, MD, PhD,
"Principles/X-ray dose:
CT/PET: basic principles."
Jay Heiken, MD, "Endolu
minal stent graft repair of
abdominal aortic aneurysms:
evaluation with MDCT."
Stuart Sagel, MD, "CT
angiography for pulmonary
embolism"; Interactive thoracic CT case discussions";
"Anatomic variants,
anomalies and pitfalls in
thoracic CT."
Marilyn Siegel, MD,
"Imaging common pediatric
abdominal masses."
Barry Siegel, MD, "PET in
women's cancers."

PRESENTATIONS
Kyongtae Bae, MD, PhD;
Victoria Chen; Jie Zheng,
PhD; Charles Hildebolt,
DDS, PhD; Premsri Barton, MD, "Dynamic MR
contrast enhancement
characteristics of breast
cancer: effect of contrast
injection rate."
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ongtae Bae, MD, PhD;
leng Hong, MD, "Deterning optimal scan delay in
-MDCT angiography."
] ongtae Bae, MD, PhD;
i ta Mody; Dennis Balfe,
1 3; Sanjeev Bhalla, MD;
1 vid Gierada, MD; Ferli ando Gutierrez, MD;
Christine Menias, MD;
] imela Woodard, MD; JinMo Goo, MD, PhD;
Charles Hildebolt, DDS,
I PhD, "Display window settings for depiction of pul| monary emboli in CT: trends
and variations among
i observers."
Jay Heiken, MD, "Imaging
of small bowel obstruction
I with MDCT."
Marilyn Siegel, MD,
"MR/CT of pediatric renal
tumors," "CT of adrenal
tumors."

SOCIETY OF INTERVENTION RADIOLOGY

29th Annual Meeting
Phoenix, Arizona
March 25-30, 2004

Daniel Brown, MD, coordinator and moderator, Categorical Course: Enteric
Access: Percutaneous vs.
Endoscopic—Which Would
You Want?

Wael Saad, MD, recipient,
Travel Award.
Suresh Vedantham, MD,
panelist, Categorical Course:
Lessons Learned—Venous
Insufficiency.

SCIENTIFIC PRESENTATIONS
Dimitrios Papadouris,
MD; Thomas Pilgram,
PhD; Daniel Brown, MD,
"Power injection of microcatheters: an in vitro comparison."

Thomas Vesely, MD, coordinator, Workshop: Venous
Access; commentator,
Central Venous Scientific
Session.

Wael Saad, MD; Michael
Darcy, MD, "Stent-grafts in
primary TIPS and in TIPS
revisions: a single center
experience."

CATEGORICAL COURSES
Daniel Brown, MD, "An
enterostomy practice is good
for your patients and you:
how to target referrals and
avoid trouble."

Wael Saad, MD, "Hepatic
artery PTA after liver transplantation: the fatal kink";
"The natural history of
hepatic artery stenosis in
liver transplant recipients";
"Transhepatic dilation of
anastomotic biliary strictures in liver transplants: significance of a patent hepatic
artery"; "Safety and efficacy
of fluoroscopic versus ultrasound guided core liver biopsies in live liver transplant
donors."

Michael Darcy, MD, "Pal
liative interventions for
symptomatic fluid collections."
PLENARY SESSIONS
Michael Darcy, MD,
"Ambulatory phlebectomy:
tips and techniques."
Suresh Vedantham, MD,
"Tumescent anesthesia: tips
and techniques."
Thomas Vesely, MD,
"Vascular access surveillance: go with the flow";
"Tips and tricks: mechanical
thrombectomy."

Thomas Vesely, MD, "Use
of the peripheral cutting balloon to treat hemodialysisrelated stenoses."
POSTER PRESENTATIONS
Wael Saad, MD, "Microbial
contamination of bile following liver transplantations: de
novo PTC versus indwelling
biliary drains."
WORKSHOPS
Daniel Brown, MD, "Gastrointestinal IR: techniques
and management."
Thomas Vesely, MD,
"Hemodialysis access."
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INTERNATIONAL
CONGRESS OF HYPERTHERMIC ONCOLOGY
&'• Scientific Meeting
St. Louis, Missouri
April 20-24, 2004
Katherine Bles, coordinator liaison, Local Arrangements Committee.
Andrei Laszlo, PhD, member, Local Arrangements
Committee.
Jacob Locke, MD, cochairman, Workshop: Whole Body
Hyperthermia Modulation of
Therapeutic Responses.
Eduardo Moros, PhD,
chairman, Local Arrangements Committee; chairman,
Robinson Award Lecture;
member, Organizing Committee; coordinator, Scientific Program Committee;
cochairman, Non-invasive
Thermometry/Imaging Special Lectures Session.
Robert Myerson, MD,
PhD, cochairman, Plenary
Symposium: New Randomized Phase III Trials; member, Local Arrangements
Committee.
Joseph Roti Roti, PhD,
chairman, Organizing Committee; chairman, Plenary
Lecture: Advances in PET
Imaging of Hypoxia; member, Local Arrangements
Committee.
William Straube, MS,
cochairman, Special
Lecture: Advances in
Hyperthermia/Thermal
Therapy Devices.
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WORKSHOPS
Eduardo Moros, PhD,
"Clinical SURLAS for superficial simultaneous thermoradiotherapy."
Robert Myerson, MD,
PhD, "Monitoring the effect
of41°C hyperthermia on
tumor hypoxia by Cu-ATSM
PET scanning."
Robert VanderWaal, PhD,
"Heat-shock induced overlap
of euchromatin and heterochromatin DNA replication."
ORAL PRESENTATIONS
Jacob Locke, MD, "Differences in response to localized ultrasound versus
waterbath hyperthermia:
clinical implications."
Tej Pandita, PhD,
"Genomic instability and
enhanced radiosensitivity in
Hsp70.1/3-deficient mice."

i

Michael Welch, PhD,
"Advances in PET imaging of
hypoxia."
Mai Xu, MD, PhD, "The
effects of 41° hyperthermia
on the DNA repair protein,
MRE 11, correlate with
radiosensitization in four
human tumor cell lines."
MEETING SUMMARY
Eduardo Moros, PhD,
"Highlights of physics/engineering presentations."

POSTER PRESENTATIONS
Bibianna Cha; Petr Novak,
PhD; William Straube, MS;
Robert Myerson, MD, PhD;
Eduardo Moros, PhD,
"Development of a LinacSURLAS-patient interface
transport."
Bibianna Cha; Petr Novak,
PhD; William Straube, MS;
Robert Myerson, MD, PhD;
Eduardo Moros, PhD,
"Designing an articulated arm
for the LINAC-SURLASpatient interface transport."
Andrei Laszlo, PhD,
"Effects of heat shock on the
state of phosphorylation of
histone H2AX."
Eduardo Moros, PhD,
"Study of the hyperthermic
effects of underlying bone on
power and temperature patterns in tissue-like phantoms
exposed to planar ultrasound."
Robert Myerson, MD, PhD,
"Simultaneous radiation therapy and hyperthermia in the
elective treatment of subclinical disease in high risk
breast carcinoma: comparison of post treatment normal
tissue effects in heated and
unheated portions of the
chest wall"; "Modeling heat
induced radiosensitization:
clinical implications"; "Monitoring the effect of 41°C
hyperthermia on tumor
hypoxia by Cu-ATSM PET
scanning."

Petr Novak, PhD; William
Straube, MS; Bibianna
Cha; Robert Myerson, MD,
PhD; Eduardo Moros,
PhD, "Preclinical evaluation
of the SURLAS using a perfused phantom;"
Petr Novak, PhD; Anurag
Singh, MD; Buck Rogers,
PhD; Jacob Locke, MD;
Andrea Zeug; William
Straube, MS; Robert
Myerson, MD, PhD;
Eduardo Moros, PhD,
"Performance of the SAHUS
temperature controller in a
perfused phantom and invivo experiments."
Petr Novak, PhD; William
Straube, MS; Bibianna
Cha; Robert Myerson, MD,
PhD; Eduardo Moros,
PhD, "Software environment
of the clinical SURLAS;"
Petr Novak, PhD; William
Straube, MS; Bibianna
Cha; Robert Myerson, MD,
PhD; Eduardo Moros,
PhD, "Safety features of the
clinical SURLAS."
Petr Novak, PhD; Buck
Rogers, PhD; Jacob Locke,
MD; Anurag Singh, MD;
Andrea Zeug; William
Straube, MS; Robert
Myerson, MD, PhD;
Eduardo Moros, PhD,
"Initial experience with the
SAHUS—a small animal
hyperthermia ultrasound
system."

Tej Pandita, PhD,
"Genomic instability and
enhanced radiosensitivity in
Hsp70.1/3-deficient mice."
Joseph Roti Roti, PhD,
"Potential effects of short
(1-5 second) thermoexposures (+15 degree C) on
DNA repair."
William Straube, MS, "The|
effect of hyperthermia applicators on radiation surface
dose for simultaneous thermoradiotherapy."
Robert VanderWaal, PhD, I
"Heat-shock induced overlap!
of euchromatin and
heterochromatin DNA
replication."
Mai Xu, MD, PhD, "The
effects of 41° hyperthermia
on the DNA repair protein,
MRE 11, correlate with
radiosensitization in four
human tumor cell lines."
Andrea Zeug; Dominic
Thompson; Petr Novak,
PhD; Kate Mazzerella;
Eduardo Moros, PhD;
Jacob Locke, MD, "Com
parison of ultrasound versus |
waterbath hyperthermia on
HeLa xenografts."
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HUMAN

SHAY,
Right: An actual human brain
is included in the traveling
exhibit, which is now at the
Science Center in Kansas,.
City, Missouri, through September 11, 2004.
Left: The PET III head scanner, one of the last

Above: The large, purple, alien-looking structures that

scanners built on-site at the Institute, was

made up the traveling brain exhibit at the St. Louis

part of Mallinckrodt Institute's contributions

Science Center have moved on but, from January 31

to the Science Center's focus on neurological

through May 2, they helped to explain the electro-

research in St. Louis. When the traveling por-

magnetic workings and diseases occurring daily in our

tion of the exhibit was taken to Kansas City,

heads. Brain: The World Inside Your Head, produced

scanner was returned to its permanent

by Pfizer Inc. in collaboration with the National Insti-

e in the Scott Avenue Imaging Center.

tutes of Health, provided adults and children with fascinating information about the most complex structure
in the known universe: the human brain.
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